At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.

A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Charlotte Allerton, Pfizer's head of medicine design, said: "The XtalPi collaboration is an opportunity to enhance our computational modelling capabilities. "We are looking forward to potentially ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Pfizer targets $4 billion in operational savings ... molecular profiles (a trend increasingly favored in precision medicine). In short, the pipeline diversity here enables near-term commercial ...

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at ...

Many dog owners have already heard about the FDA warning and seen the articles on the terrible side effects experienced by ...